The Centers for Disease Control and Prevention (CDC) with the help of the American Pharmacists Association (APhA) Foundation has developed a tool kit for instituting collaborative practice agreements between healthcare providers and pharmacists, which is intended to improve healthcare quality.
The Centers for Disease Control and Prevention (CDC) with the help of the American Pharmacists Association (APhA) Foundation has developed a tool kit for instituting collaborative practice agreements between healthcare providers and pharmacists, which is intended to improve healthcare quality.
The target audience for this resource material is pharmacists, other healthcare providers, payers, and decision-makers of collaborative practice agreements. Under state law, a pharmacist collaborative practice agreement is “a formal agreement in which a licensed provider makes a diagnosis, supervises patient care, and refers patients to a pharmacist under a protocol that allows the pharmacist to perform specific patient care functions,” according to CDC.
“Research shows us that a patient’s control of their blood pressure improves when their care is provided by a team of health professionals,” said David Callahan, MD, with CDC. “This tool kit will play an invaluable role in allowing physicians and pharmacists to work together to give patients optimal are and save lives by controlling blood pressure.”
The content for the tool kit was developed with input from APhA Foundation following a consortium on collaborative practice agreements and pharmacists’ patient care services held in January 2012. Case studies from Osterhous Pharmacy in eastern Iowa, Goodrich Pharmacy in Minnesota, and El Rio Community Health Center in Arizona were good examples of pharmacist patient care services performed under collaborative practice agreements.
The document also outlined action steps for pharmacists to help build and strengthen these collaborative agreements:
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More